Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) raised nearly C$1 million in fresh capital as it continues to expand production internationally.
The psychedelics supplier closed the second tranche of its private placement Tuesday, raising C$395,000 and bringing total proceeds to C$934,000. The financing, which saw participation from company insiders, was structured as units priced at C$0.30, with each unit including a share and half-warrant exercisable at CAD$0.40 through January 2027.
The capital raise comes as Optimi says it completed manufacturing its largest batch of MDMA capsules to date – over 4,000 units capable of treating more than 1,000 patients. The production milestone follows successful one-year stability testing of its MDMA formulation, with a two-year testing program now underway.
“Additionally, our customer feedback is that our MDMA offering is often more cost-effective than other limited options in the market, making it an attractive solution for both patients and healthcare providers,” CEO Dane Stevens said in a statement. “We are excited to be producing affordable and stable inventory in-house under our Drug Establishment Licence. Combined with our capacity to store up to C$50 million worth of scheduled substances in our secure vault, Optimi is uniquely positioned to meet increased demand efficiently and reliably.”
Aside from supplying Australian physicians treating PTSD patients under the country’s Authorized Prescriber Scheme, Optimi is supporting a Phase 2 clinical trial for PTSD in Israel and fulfilling Special Access Program requests in Canada. The company also inked a psilocybin supply deal last year with the Mātai Medical Research Institute in New Zealand, on behalf of the Tū Wairua Project.
As part of Monday’s announcement, Optimi also disclosed a debt settlement arrangement, converting approximately C$98,500 in marketing-related obligations into equity through the issuance of 458,145 shares at C$0.215 each.
Psychedelics Archives – Green Market Report Read More
